Format
Sort by

Send to

Choose Destination

Search results

Items: 8

1.

Effects of lorcaserin on pre-existing valvulopathy: A pooled analysis of phase 3 trials.

Weissman NJ, Smith SR, Fain R, Hall N, Shanahan WR.

Obesity (Silver Spring). 2017 Jan;25(1):39-44. doi: 10.1002/oby.21695.

PMID:
27888609
2.

Lorcaserin for Smoking Cessation and Associated Weight Gain: A Randomized 12-Week Clinical Trial.

Shanahan WR, Rose JE, Glicklich A, Stubbe S, Sanchez-Kam M.

Nicotine Tob Res. 2016 Nov 4. pii: ntw301. [Epub ahead of print]

PMID:
27815511
3.

Barriers to drug adherence in the treatment of urea cycle disorders: Assessment of patient, caregiver and provider perspectives.

Shchelochkov OA, Dickinson K, Scharschmidt BF, Lee B, Marino M, Le Mons C.

Mol Genet Metab Rep. 2016 Jul 20;8:43-7. doi: 10.1016/j.ymgmr.2016.07.003.

4.
5.

Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser.

Scheinberg MA, Hislop CM, Martin RS.

Expert Opin Biol Ther. 2016;16(5):723-33. doi: 10.1517/14712598.2016.1169270. Review.

PMID:
27051973
6.

Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials.

Nagamani SC, Diaz GA, Rhead W, Berry SA, Le Mons C, Lichter-Konecki U, Bartley J, Feigenbaum A, Schulze A, Longo N, Berquist W, Gallagher R, Bartholomew D, Harding CO, Korson MS, McCandless SE, Smith W, Vockley J, Kronn D, Zori R, Cederbaum S, Merritt JL 2nd, Wong D, Coakley DF, Scharschmidt BF, Dickinson K, Marino M, Lee BH, Mokhtarani M.

Mol Genet Metab. 2015 Sep-Oct;116(1-2):29-34. doi: 10.1016/j.ymgme.2015.08.002.

7.

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.

Furie RA, Leon G, Thomas M, Petri MA, Chu AD, Hislop C, Martin RS, Scheinberg MA; PEARL-SC Study..

Ann Rheum Dis. 2015 Sep;74(9):1667-75. doi: 10.1136/annrheumdis-2013-205144.

PMID:
24748629
8.

Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice.

Fraser H, Hislop C, Christie RM, Rick HL, Reidy CA, Chouinard ML, Eacho PI, Gould KE, Trias J.

J Cardiovasc Pharmacol. 2009 Jan;53(1):60-5. doi: 10.1097/FJC.0b013e318195bfbc.

PMID:
19129734
Items per page

Supplemental Content

Loading ...
Support Center